Welcome!

News Feed Item

Cyberonics Reports Fiscal 2015 First Quarter Results

Year-on-year sales increase for the 25th consecutive quarter

HOUSTON, Aug. 21, 2014 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter ended July 25, 2014. 

Quarterly highlights1 

Operating results for the first quarter of fiscal 2015 compared to the first quarter of fiscal 2014, and other achievements, include:

  • Worldwide net product sales of $72.0 million, an increase of 6.8%;
  • Strong international net sales of $13.2 million, an increase of 14.5% on a constant currency basis;
  • U.S. net product sales reached a new high of $58.8 million, an increase of 4.4% over the comparable quarter of the prior year;
  • Income from operations of $22.0 million increased by 12.4% from an adjusted income from operations in the prior year of $19.6 million;
  • Adjusted non-GAAP income per diluted share of $0.53 compared with adjusted non-GAAP income per diluted share of $0.45, an increase of 18%;
  • Submission of the ProGuardianREST in-home seizure monitoring system to the Food and Drug Administration ("FDA") for regulatory clearance;
  • Submission of the first module, comprising clinical data, to support eventual CE mark approval of the VITARIA™ system (Autonomic Regulation Therapy for chronic heart failure);
  • Discussions with the FDA to agree on next steps for U.S. regulatory process of the AspireSR® generator; and
  • Receipt of initial regulatory approvals for the new manufacturing facility in Costa Rica.

1

The financial and operating results for the thirteen weeks ended July 25, 2014 and July 26, 2013 include and exclude certain items for the purposes of non-GAAP comparisons. As discussed below under "Use of Non-GAAP Financial Measures" in this release, the company refers to and makes comparisons with certain non-GAAP financial measures. Investors should consider non-GAAP measures in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the attached non-GAAP reconciliation. Numbers may be affected by rounding.

Results and objectives

"Cyberonics continued to deliver increased sales and earnings during our first quarter of fiscal 2015 over the same quarter last year," commented Dan Moore, President and Chief Executive Officer.  "However, overall net sales for the quarter fell short of our expectations by approximately $1 million.  The softness was in our U.S. business, where unit sales grew by 2%, and net sales increased by 4% over the comparable period in the prior year to a new high of $58.8 million.  We have not yet reestablished year-on-year growth in new patient adoption.  While we expect greater productivity in the second quarter from our new field sales employees, the entire Cyberonics U.S. commercial team remains focused on restoring new patient growth.  The team has implemented additional initiatives for the second quarter targeting comprehensive epilepsy centers and physicians who have been inconsistent in their utilization of VNS Therapy.  We remain optimistic about the potential for VNS Therapy in this underserved market.  As mentioned last quarter, we are increasing our investment in sales and marketing significantly for fiscal 2015.

"International sales showed consistent growth with unit sales increasing by 14% and net sales of $13.2 million increasing by 14% on a constant currency basis.  Again this quarter, Europe and Latin America led the growth with solid country performances throughout their respective regions.  The continuation of our limited market launch of the AspireSR generator in the U.K. and Germany is in line with our expectations.  Several accounts have reordered the product, and penetration of the AspireSR generator in these countries is estimated at 17%, and has been accompanied by a price increase.

"VNS Therapy implants in Japan grew by an estimated 20% over the same quarter in the prior year.  If this level of growth is sustained, Japan will become one of our larger single-country markets this fiscal year.  We previously discussed our plan to hire direct employees in that country, and we now expect to hire the first of these new employees by the end of the second quarter.

"We have had constructive discussions with the FDA to ascertain next steps for U.S. approval for the AspireSR generator.  While we are encouraged by this progress and are not planning another study to support the U.S. regulatory submission, approval could still require further clinical work.  The AspireSR generator is the first closed-loop VNS Therapy System, and is an important addition to our product portfolio, providing physicians and patients with another foundational treatment option for drug-resistant epilepsy, as we have already seen in the European limited launch.

"We continue to make progress on the ProGuardian platform, with a recent FDA regulatory submission of ProGuardianREST.  We anticipate a limited market launch in Europe in our fiscal third quarter.  We continue to anticipate regulatory submissions for our Centro generator in the current fiscal year.

"Dr. Inder Anand, Professor of Medicine at the University of Minnesota and chair of the ANTHEM-HF clinical study steering committee, will present the results of our ANTHEM-HF clinical study of Autonomic Regulation Therapy for chronic heart failure at the European Society of Cardiology meeting on September 1.  Regulatory submission to obtain a CE Mark is now underway with the recent submission of the first module.  We expect to complete the submission before the end of the calendar year," concluded Mr. Moore.

Stock Repurchase Update

Cyberonics purchased 189,000 shares on the open market in the first quarter of fiscal 2015, leaving 551,000 shares for repurchase under the current authorization.  We expect to complete this program by the end of fiscal year 2015.

Fiscal 2015 guidance

Cyberonics is reaffirming guidance for fiscal 2015 as follows:

Net sales are expected to be in the range of $300 million to $307 million. The assumptions used in setting this range include:

  • Growth of approximately 10%, after adjusting fiscal 2014 for the single country order of $4.7 million, and the final recognition of license revenue of $1.5 million;
  • Worldwide unit growth of approximately 7%;
  • Low to mid-single-digit growth in U.S. new patient implants, an adjustment to our prior assumption;
  • Mid-single-digit growth in U.S. replacement implants;
  • Continued international sales growth in the low to mid-teens; and
  • Euro/Dollar exchange rate of $1.35.

Gross profit margin is expected to be between 90.0% and 91.0%.

Income from operations is expected to be in the range of $96 million to $99 million.  The company anticipates an adjusted effective tax rate of approximately 35% for fiscal 2015, which assumes the renewal of the R & D tax credit.

Adjusted net income for fiscal 2015 is expected to be in the range of $62 million to $64 million.

The company expects adjusted diluted earnings per share (EPS) will be in the range of $2.33 to $2.39.

Please refer to the table on the last page of this release.

Additional details will be provided during today's conference call and in an investor presentation, which is available in the investor relations section of Cyberonics' corporate website at http://www.cyberonics.com.

Use of non-GAAP financial measures

In this press announcement, management has disclosed financial measurements that present financial information not in accordance with Generally Accepted Accounting Principles (GAAP).  These measurements are not a substitute for GAAP measurements, although company management uses these measurements as aids in monitoring the company's ongoing financial performance quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies.  Adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the income from operations, net income and income per diluted share of the company including and excluding items management consider to be unusual.  Management uses and presents these measures because management believes that they facilitate an understanding of the financial impact of unusual items on the company's short- and long-term financial trends.  Management also uses adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis.  Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) measures the adjusted non-GAAP income from operations of the company and excludes the aforementioned items, as well as non-cash equity compensation and other income (expense) items.

Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly-titled measures used by other companies.  Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Please refer to the attached reconciliations between GAAP and non-GAAP financial measures.

First-Quarter Results Webcast and Conference Call Instructions

Cyberonics will host a conference call today, August 21, 2014, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to review its results of operations for the fiscal year 2015 first quarter, followed by a question and answer session.

The conference call will be available to interested parties through a live audio webcast in the investor relations section of Cyberonics' corporate website at www.cyberonics.com.  To listen to the conference call live by telephone, dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.).  The conference ID is 76419439.

Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the Cyberonics website, where it will be archived and accessible for approximately 12 months.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics offers the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable.  We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable.  Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning increasing our epilepsy market penetration and sales growth, completing product development work, conducting and completing clinical studies, applying for and obtaining regulatory approvals, launching new commercial products, completing our share repurchase program and achieving our financial guidance for fiscal 2015.  Our actual results may differ materially.  Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of the VNS Therapy System and sales of our products; the development and satisfactory completion of clinical studies; the achievement of regulatory approval for new products, including use of the VNS Therapy System for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by the Centers for Medicare & Medicaid Services, state Medicaid agencies and private insurers; the presence or absence of intellectual property protection and potential infringement claims; maintaining compliance with government regulations; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC).  For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 25, 2014.

Contact information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
[email protected]

 

 

CYBERONICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)




 For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013








Net sales


$

72,003,966



$

68,872,357


Cost of sales



6,410,392




6,544,033


Gross profit



65,593,574




62,328,324


Operating expenses:









Selling, general and administrative



33,027,606




29,306,271


Research and development



10,562,754




11,975,165


Litigation settlement



––




7,442,847


Total operating expenses



43,590,360




48,724,283


Income from operations



22,003,214




13,604,041


Interest income, net



37,666




43,415


Other income (expense), net



171,455




(130,691)


Income before income tax



22,212,335




13,516,765


Income tax expense



8,693,513




4,842,839


Net income


$

13,518,822



$

8,673,926











Basic income per share


$

0.51



$

0.32


Diluted income per share


$

0.50



$

0.31











Shares used in computing basic income per share



26,674,134




27,513,191


Shares used in computing diluted income per share



26,915,388




27,845,495


 

CYBERONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited except where indicated)




July 25, 2014


April 25, 2014






(Audited)


ASSETS









Current Assets







Cash and cash equivalents


$

107,679,362



$

103,299,116


Short-term investments



25,047,700




25,028,957


Accounts receivable, net



48,297,114




50,674,041


Inventories



18,685,693




17,630,111


Deferred tax assets



9,446,096




17,208,365


Other current assets



5,941,944




6,590,612


Total Current Assets



215,097,909




220,431,202


Property, plant and equipment, net



40,088,068




39,534,873


Intangible assets, net



11,329,978




11,654,690


Long-term investments



15,944,427




15,944,427


Deferred tax assets



6,218,609




5,770,644


Other assets



1,244,242




855,558


Total Assets


$

289,923,233



$

294,191,394




















LIABILITIES AND STOCKHOLDERS' EQUITY











Current Liabilities









Accounts payables and accrued liabilities


$

24,150,468



$

29,897,697


Total Current Liabilities



24,150,468




29,897,697


Long-term Liabilities



1,448,860




5,193,853


Total Liabilities



25,599,328




35,091,550


Total Stockholders' Equity



264,323,905




259,099,844


              Total Liabilities and Stockholders' Equity


$

289,923,233



$

294,191,394


 


CYBERONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)




For the Thirteen Weeks Ended




July 25, 2014




July 26, 2013











Cash Flow From Operating Activities:









Net income


$

13,518,822



$

8,673,926


Non-cash items included in net income:









Depreciation



1,235,902




1,010,839


Amortization



324,712




346,162


Stock-based compensation



3,512,443




3,153,499


Deferred income tax



3,402,023




(483,988)


Deferred license revenue amortization



-




(1,467,869)


Other



(160,061)




(13,497)


Changes in operating assets and liabilities:









Accounts receivable, net



2,129,438




(366,782)


Inventories



(1,057,344)




149,041


Litigation settlement



-




7,111,090


Other current and non-current assets



238,129




424,453


Other current and non-current liabilities



(5,046,273)




(9,049,218)


Net cash provided by operating activities



18,097,791




9,487,656


Cash Flow From Investing Activities:









Short-term investments



6,459




(10,300,129)


Intangible asset purchases



-




(1,250,000)


Purchases of property, plant and equipment



(1,815,500)




(5,533,847)


Net cash used in investing activities



(1,809,041)




(17,083,976)


Cash Flow From Financing Activities:









Proceeds from exercise of options for common stock



1,509,758




2,613,639


Cash settlement of stock units



(786,361)




(936,115)


Purchase of treasury stock



(13,782,231)




(12,964,495)


Realized excess tax benefit



1,264,795




4,474,196


Net cash used in financing activities



(11,794,039)




(6,812,775)


Effect of exchange rate changes on cash and cash equivalents



(114,465)




22,358


Net increase (decrease) in cash and cash equivalents



4,380,246




(14,386,737)


Cash and cash equivalents at beginning of period



103,299,116




120,708,572


Cash and cash equivalents at end of period


$

107,679,362



$

106,321,835


 

 


RECONCILIATION BETWEEN GAAP AND NON-GAAP FINANCIAL MEASURES

 (Unaudited)


The following table sets forth the reconciliation between GAAP income from operations and adjusted non-GAAP income from operations (unaudited):




For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Income from operations


$

22,003,214



$

13,604,041


License fee(1)



-




(1,467,869)


Litigation settlement



-




7,442,847


Adjusted non-GAAP income from operations


$

22,003,214



$

19,579,019


 

The following tables set forth the reconciliation between GAAP and our non-GAAP financial measures for net income and diluted income per share (unaudited):




For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Net income


$

13,518,822



$

8,673,926


License fee, net of tax (1)



-




(920,869)


Litigation settlement, net of tax



-




4,776,075


Tax expense associated with change in international structure



587,670




-


Benefit assumed from extension of R&D tax credit (2)



217,436




-


Adjusted non-GAAP net income


$

14,323,928



$

12,529,132




















Diluted income per share


$

0.50



$

0.31


License fee, net of tax (1)



-




(0.03)


Litigation settlement, net of tax



-




0.17


Tax expense associated with change in international structure



0.02




-


Benefit assumed from extension of R&D tax credit (2)



0.01




-


Adjusted non-GAAP diluted income per share (3)


$

0.53



$

0.45




(1)

Completion of license fee recognition.

(2)

Consistent with annual guidance and prior year.

(3)

Numbers may be affected by rounding.








For the Thirteen Weeks Ended



July 25, 2014


July 26, 2013










Adjusted non-GAAP net income


$

14,323,928



$

12,529,132


Interest income, net



(37,666)




(43,415)


Other (income) expense, net



(171,455)




130,691


Depreciation and amortization



1,560,614




1,357,001


Stock based compensation



3,512,443




3,153,499


Income tax expense – adjusted for the income tax impact of non-GAAP items



7,888,407




6,962,611


Adjusted EBITDA


$

27,076,271



$

24,089,519


 

 


NET SALES

Fiscal 2014 and Guidance for Fiscal 2015

($000s)



Fiscal 2014

 


Growth over

Fiscal 2013


Fiscal 2015

Mid-Point


Growth over

Fiscal 2014


Fiscal 2015

Guidance Range


Range of Growth

over Fiscal 2014

























U.S.

$

225,455


7.9

%


$

247,500


9.8

%


$

245,000

-

$

250,000


8.7

%

-

10.9

%

























International


50,345


14.5

%



56,000


11.2

%



55,000

-


57,000


9.2

%

-

13.2

%

























Net sales(1)

$

275,800


9.1

%


$

303,500


10.0

%


$

300,000

-

$

307,000


8.8

%

-

11.3

%

























Single country order

$

4,746


N/A



$

-


N/A






































Net product sales

$

280,546


11.0

%


$

303,500


8.2

%


$

300,000

-

$

307,000


6.9

%

-

9.4

%

























Licensing revenue

$

1,468


-1.7

%


$

-


N/A






































Net sales

$

282,014


10.9

%


$

303,500


7.6

%


$

300,000

-

$

307,000


6.4

%

-

8.9

%



(1)

Net product sales excluding single country order

SOURCE Cyberonics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"There is a huge interest in Kubernetes. People are now starting to use Kubernetes and implement it," stated Sebastian Scheele, co-founder of Loodse, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Providing secure, mobile access to sensitive data sets is a critical element in realizing the full potential of cloud computing. However, large data caches remain inaccessible to edge devices for reasons of security, size, format or limited viewing capabilities. Medical imaging, computer aided design and seismic interpretation are just a few examples of industries facing this challenge. Rather than fighting for incremental gains by pulling these datasets to edge devices, we need to embrace the i...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operations and Information Security organizations together. Capital Ones DevOpsSec practice is based upon three "pillars" – Shift-Left, Automate Everything, Dashboard Everything. Within about three years, from 100% waterfall, C...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walked through how Octob...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of Dev...
SYS-CON Events announced today that Catchpoint, a leading digital experience intelligence company, has been named “Silver Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Catchpoint Systems is a leading Digital Performance Analytics company that provides unparalleled insight into your customer-critical services to help you consistently deliver an amazing customer experience. Designed for digital business, C...
"We formed Formation several years ago to really address the need for bring complete modernization and software-defined storage to the more classic private cloud marketplace," stated Mark Lewis, Chairman and CEO of Formation Data Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.